Effect of Edaravone in prevention of contrast-induced acute kidney injury (CI-AKI)

Effect of Edaravone in prevention of contrast-induced acute kidney injury (CI-AKI) in hospitalized patients in Shahid Madani Tabriz requiring coronary angiography at 1399 and 1400

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201108049311N5

Enrollment

Registered

2021-09-09

Start date

2021-05-20

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy acute kidney injury (CIN-AKI). Other injury of kidney

Interventions

Intervention 1: Intervention group:Recieving Edaravone drug from Zist daru pharmaceutical company (in the form of 30 mg solutions in 20 cc one hour before angiography at a dose of 30 mg by intravenous

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: Candidates for coronary angiography Patients with kidney injury stage 4 and Stage 3B with GFR between 15 and 45 Patients with underlying diseases such as diabetes and lupus that cause renal failure

Exclusion criteria

Exclusion criteria: Pregnancy lactation Age over than 75 years 5-fold increased liver enzymes

Design outcomes

Primary

Measure	Time frame
Serum creatinine level. Timepoint: Day 5 of contrast injection. Method of measurement: Biochemical methods.;Hospitalization duration. Timepoint: Number of hospitalization days after angiography. Method of measurement: Patients' documents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Samad Ghaffari Bavil

Tabriz University of Medical Sciences

ghafaris@gmail.com+98 41 3335 7767

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026